Abstract

Chronic polypous rhinosinusitis does not subject to complete medicinal control; it is difficult to predict the prospects of the pathology development in each individual patient. Therefore, the search of new regimens of treatment of these patients is still in progress. An international consensus published in 2016, considers, inter alia, various groups of drugs for conservative treatment of polypous rhinosinusitis from the viewpoint of evidence-based medicine. We conducted a retrospective analysis of outpatient records and personal data of 1059 patients with polypous rhinosinusitis who underwent outpatient and inpatient treatment at the period from February 2016 to March 2018 in Moscow, Moscow Region and 26 regions of Russia. According to the results, in outpatient treatment, the basic therapy with intranasal glucocorticosteroids was performed in 92.4%, irrigation therapy – in 82.2% of cases, antihistamines were recommended in 79.4%. In case of hospitalization for surgical treatment, 16.6% of patients in Russian regions and 24% in Moscow Region had received no preliminary therapy for 6 months before hospitalization. In general, analyzing the management and treatment regimens of the patients with polypous rhinosinusitis, we found almost no deviations from the present-day domestic and foreign clinical guidelines. However, we observed prescription of some intranasal glucocorticosteroids, the leaflets of which contain no indications for polypous rhinosinusitis treatment.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call